StemEx® is expanding: Pivotal Trial Nears Completion

StemEx, gamida cell, stem cellsExclusive announcement – download full press release here

Gamida Cell’s  flagship product, StemEx®, is currently being studied in the clinic as a treatment for hematological malignancies including leukemia and lymphoma in a single arm, global, pivotal registration study.

StemEx is poised to answer the dire unmet clinical need in the field of bone marrow transplantation by supplying alternative cell grafts to the 50,000 patients with hematological malignancies, who are indicated for transplantation but do not have a matched family related bone marrow donor. The market potential of StemEx is estimated at more than one billion USD.

Clinical data for this pivotal trial is expected in Q3 of 2012 and projects to expand the product are already underway. Download the full press release for comprehensive overview of Gamida Cell's current and future work.

Yael Margolin, President & CEO, Gamida Cell Ltd will be going into more detail and presenting on the crucial late stage clinical lessons learned at the World Stem Cells & Regenerative Medicine Congress 2012 – "StemEx pivotal trial completed – countdown to results"

Registration is now open and delegate prices currently start at £625 so make sure you register today before our early bird offers expire.